173 related articles for article (PubMed ID: 30369425)
1. Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
Schlei Z; Tan W; Faber MG; Chen H; Meagher A; Dy GK
Clin Lung Cancer; 2018 Nov; 19(6):467-475. PubMed ID: 30369425
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T
Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156
[TBL] [Abstract][Full Text] [Related]
4. A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
Minchom A; Mak D; Gunapala R; Walder D; Kumar R; Yousaf N; Hodgkiss A; Bhosle J; Popat S; O'Brien MER
PLoS One; 2019; 14(11):e0225509. PubMed ID: 31765437
[TBL] [Abstract][Full Text] [Related]
5. Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B
Baldi M; Behera D; Kaur J; Kapoor R; Singh N
Clin Lung Cancer; 2017 Jul; 18(4):432-435. PubMed ID: 28073680
[TBL] [Abstract][Full Text] [Related]
6. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
Singh N; Baldi M; Kaur J; Muthu V; Prasad KT; Behera D; Bal A; Gupta N; Kapoor R
Cancer; 2019 Jul; 125(13):2203-2212. PubMed ID: 30825389
[TBL] [Abstract][Full Text] [Related]
7. Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.
Stoffregen CC; Odin EA; Carlsson GU; Kurlberg GK; Björkqvist HG; Tångefjord MT; Gustavsson BG
Anticancer Drugs; 2016 Jun; 27(5):439-46. PubMed ID: 26825869
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
9. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
12. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
Suwanrusme H; Meyer ML; Green MR
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S56-60. PubMed ID: 15117426
[TBL] [Abstract][Full Text] [Related]
14. Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study.
Takeda Y; Naka G; Katsuya Y; Kobayashi K; Suzuki M; Hashimoto M; Hirano S; Uemura Y
BMC Cancer; 2023 Aug; 23(1):800. PubMed ID: 37633908
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy].
Zeng X; Zhou C; Ouyang M; Qin Y; Yang H; Peng Y; Liu S
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):868-72. PubMed ID: 26887521
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.
Takagi Y; Hosomi Y; Sunami K; Nakahara Y; Okuma Y; Yomota M; Shimokawa T; Nagamata M; Iguchi M; Okamoto H; Okamura T; Shibuya M
Oncologist; 2014 Nov; 19(11):1194-9. PubMed ID: 25260366
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
20. Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
Clark SK; Anselmo LM
J Oncol Pharm Pract; 2019 Oct; 25(7):1645-1650. PubMed ID: 30319062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]